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Summary 
Objectives: Development of risk stratification criteria for predicting mortality in post-infarction 
patients taking into account LVEF and heart-rate turbulence (HRT). 
Methods: Based on previous results the two parameters LVEF (continuously) and turbulence 
slope (TS) as an indicator of the HRT were combined for risk stratification. The method has been 
applied within two independent data sets (the MPIP-trial and the EMIAT-study). 
Results: The criteria were defined in order to match the outcome of applying LVEF ≤ 30 % in 
sensitivity. In the MPIP trial the optimal criteria selected are TS normal and LVEF ≤ 21 % or TS 
abnormal and LVEF ≤ 40 %. Within the placebo group of the EMIAT-study the corresponding 
criteria are: TS normal and LVEF ≤ 23 % or TS abnormal and LVEF ≤ 40 %. Combining both 
studies the following criteria could be obtained: TS normal and LVEF ≤ 20 % or TS abnormal 
and LVEF ≤ 40 %. In the MPIP study 83 out of the 581 patients (= 14.3 %) are fulfilling these 
criteria. Within this group 30 patients have died during the follow-up. In the EMIAT-trial 218 out 
of the 591 patients (= 37.9 %) are classified as high risk patients with 53 deaths. Combining both 
studies the high risk group contains 301 patients with 83 deaths (ppv = 27.7 %). Using the 
MADIT-criterion as classification rule (LVEF ≤ 30 %) a sample of 375 patients with 85 deaths 
(ppv = 24 %) can be selected. 
Conclusions: The stratification rule based on LVEF and TS is able to select high risk patients 
suitable for implanting an ICD. The rule performs better than the classical one with LVEF alone. 
The high risk group applying the new criteria is smaller with about the same number of deaths 
and therefor with a higher positive predictive value. The classification criteria have been 
validated within a bootstrap study with 100 replications. In all samples the rule based on TS and 
LVEF (= NEW) was superior to LVEV alone, the high risk group has been smaller ( n ± s: 301 ± 
14.5 (NEW) vs. 375 ± 14.5 (LVEF)) and the positive predictive value was larger ( p ± s: 27.2 ± 
2.6 % (NEW) vs. 23.3 ± 2.2 % (LVEF)). The new criteria are less expensive due to a reduced 
number of high risk patients selected. 
 
   
3
Introduction 
The development of the implantable cardioverter defibrillator (ICD)1 changed the treatment of 
patients with malignant arrhythmias. Several randomized clinical trials2-8 have shown that 
arrhythmic mortality can be effectively reduced by this therapy. However, the question arises as 
to which patients will truly benefit from prophylactic ICD therapy. 
Risk stratification is a major topic due to the large number of potential candidates and the related 
costs. Therefore the development of selection criteria remains a serious problem and is the target 
of many investigations. Usually a combination of various tests are recommended. In a recent 
meta-analysis9 a three step procedure was proposed based on signal averaged ECG and LVEF in 
the first stage followed by ambulatory ECG in the second stage and finally EPS in the third stage. 
The authors estimated that about 11.8 % of all post MI patients are classified as having a high 
risk. 
Huikuri et. al.10 investigated the predictive power of various parameters in the ß-blocking era. 
Their conclusions was that the common markers have limited power in identifying high risk 
patients. In a following editorial Moss11 recommended that at present it is probably the best to use 
LVEF as the only marker with a cut-off level of 30 % or 35 %. 
The Task Force on Sudden Cardiac Death of the European Society of Cardiology recently 
recommended a risk stratification strategy which combines a marker of structural damage, such as 
depressed left ventricular ejection fraction (LVEF), with markers of autonomic imbalance12. 
Heart-rate turbulence (HRT) is a powerful new risk predictor in survivors of myocardial 
infarction13 which represents a measure of the autonomic response to postextrasystolic pauses 
after singular ventricular premature complexes (VPC)14-16. In a study that developed the concept 
of HRT13, HRT and LVEF were found to be the only independent predictors of subsequent 
mortality in post-infarction patients.  
The goal of this study was to develop a risk-stratification algorithm for the prediction of mortality 
in post-infarction patients that makes use of HRT and LVEF and which can be adapted to various 
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mortality rates and sensitivity requirements. Data from the MPIP-study17 and the EMIAT-trial18 
were used to develop the algorithm for selecting high-risk patients.  
 
Methods 
Patient population 
a) MPIP-trial 
The MPIP study17 enrolled survivors of acute myocardial infarction, aged ≤ 70 years, and 
followed them for a period of 2.5 years. Patients were excluded from the current analysis because 
of atrial fibrillation, no VPB during Holter monitoring, missing LVEFs or because of technically 
insufficient or missing Holter recordings. Five hundred eighty-one patients were used in the 
analysis. Their clinical characteristics are shown in Table 1. During the follow-up period, 19 % 
(77 out of 581) of the patients died. 
b) EMIAT-trial placebo-arm 
The primary goal of this randomized trial was to compare the effect of Amiodarane against 
placebo on total mortality18. Altogether 1168 patients have been enrolled in that study. The main 
inclusion crieterion had been a LVEF ≤ 40 %. For the purpose of developing a classification rule 
all patients from the EMIAT-trial randomized into the placebo-arm were used (n = 591 patients 
with 82 deaths). The patients were followed up for about 2 years. The basic data of this sample 
are also shown in table 1.  
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Table 1: Basis data of both studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment of the risk predictors 
Holter recordings were performed in the second or third week after the index infarction. Initially, 
the Holter tapes were processed with a Laser Holter 8000 System (Marquette Medical Systems, 
WI, USA). After visual inspection and manual editing, computer files were generated listing RR 
interval duration (sampling frequency 128 Hz) and QRS morphological classifications on a beat-
to-beat basis. 
Both parameters of HRT, Turbulence Onset (TO) and Turbulence Slope (TS) were assessed using 
previously published methods13. LVEF was quantified by radionuclide ventriculography. 
 
591 31  (16 – 40) 581 46 ( 24 – 72 ) 
591 4,4 ( ,7 – 17,7 ) 581 5,9 ( ,6 – 25,1 ) 
n Median 
EMIAT 
Median 
MPIP  
LVEF 
(5% – 95%)  n (5% – 95%)  
TS  
509 504 1013
82 77 159
591 581 1172
censored 
dead 
Status  
Total 
EMIAT MPIP  
STUDY  
Total
419 446 865 
172 135 307
591 581 1172
normal 
abnormal 
TS  
Total 
EMIAT MPIP  
STUDY  
Total
 
   
6
Statistics 
A Cox-Model19 was used for the analysis. Based on the results of previous analyses only LVEF 
(continuously) and the turbulence slope (TS) as a measure of the heart rate turbulence (HRT) 
have been included in the model. In order to determine the appropriate relationship between 
LVEF and total mortality smoothing splines and fractional polynomials20-22 have been applied. 
The identification of high risk patients can be based on several criteria. One way could be to use 
the standard procedure (LVEF ≤ 30 %) and to select those patients with the same risk or a greater 
one. Another approach could be to assess optimal cutpoints in applying the CART procedure23.  
For any risk stratification procedure certain parameters can be calculated in order to describe the 
outcome of a particular. The high risk group can be described by the sample size, the average 
mortality rate at a certain time t and the range (t = 2 years have been used), the sensitivity (= per-
centage of deaths in that risk group divided by the total number of deaths),  the positive predictive 
value (= percentage of deaths in that particular sample). This value is approximately the same as 
the average 2-years mortality rate due the small number of censored individuals within the two 
years follow-up. 
Each decision rule has to be validated. The best way would be either to split the data available in 
a trainings- and a validation sample or to use new data. The disadvantage with the two studies 
available is the reduced number of events and the missing of new data. In the situation where no 
validation sample is available a technique called bootstrap can be used24, 25. The idea is simple. 
Based on the data available new samples of the same size are generated by random selection with 
replacement. This means some of the patients are more than one times in a bootstrap-sample 
whereas others are missing. This procedure can be repeated as often as desired. The application of 
a decision rule on the bootstrap samples can be used to describe the performance in new patients 
in form of mean and standard deviations or range. In order to obtain these values 100 bootstrap 
samples have been generated. 
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Results 
The optimal form to model the influence of LVEF on total mortality was obtained by using a 
logarithmic transformation. Fig. 1 shows the influence of LVEF and TS on the 2-years mortality 
rate varying between 5 % and 65 % in both samples. The effect of TS on mortality can also be 
seen from fig. 1. Using the recent MADIT II criterion8 (LVEF ≤ 30 %), the 2-years mortality rate 
is 24 % or higher in the MPIP study and ≥ 21 % in the EMIAT-trial.   
Identifying the patients with similar 2-years mortality rates using LVEF and TS the following 
criteria can be obtained.  
 MPIP  EMIAT  total 
TS normal: LVEF ≤ 21 %  LVEF ≤ 23 %  LVEF ≤ 20 % 
TS abnormal: LVEF ≤ 40 %  LVEF ≤ 40 %  LVEF ≤ 40 % 
 
Applying these criteria obtained for both samples altogether 301 patients are classified as high 
risk patients with 83 deaths (ppv  = 27,6 %). Using the MADIT II criteria (LVEF ≤ 30 %) the 
high risk group contains 375 patients with 85 deaths (ppv = 22.7 %) (s. Table 2). 
The selection rule based on LVEF and TS is able to identify a smaller number of high risk 
patients by nearly identical number of deaths. 
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Figure. 1:  Influence of LVEF alone and in combination with turbulence slope (= TS) on the 
2-years all cause mortality rate for both studies considered. 
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Table 2: Patients in the high-risk group 
 
 
 EMIAT  MPIP   total  
 n  dead % n  dead % n  dead % 
total 591 82 13,9 581 77 13,3 1172 159 13,6 
          
LVEF ≤ 30% 278 53 19,1 97 32 33,0 375 85 22,7 
          
TS=0, LVEF ≤ 20% 46 11 23,9 3 1 33,3 49 12 24,5 
TS=1, LVEF ≤ 40% 172 42 24,4 80 29 36,3 252 71 28,2 
together 218 53 24,3 83 30 36,1 301 83 27,6 
 
 
Validation 
In order to validate these criteria 100 bootstrap samples all of size n = 1172 have been generated. 
Using LVEF ≤ 30 % for identifying high risk patients the size of that group was between 343 and 
419 patients ( n ± s: 375 ± 14.5). Applying the new criteria the size of the high risk group varied 
between 265 and 346 patients ( n ± s: 301 ± 14.5). In all samples the high risk group based on the 
new criteria was smaller than using LVEF alone. The positive predictive values varied between 
18 % and 28 % for LVEF alone ( x ± s: 22.3 ± 2.2 %) and between 20 % and 33 % ( x ± s: 27.2 ± 
2.6 %) for the new criteria. Again in each bootstrap sample the ppv for the new criteria was larger 
than for LVEF alone (s. fig. 2). 
In summary: the new criteria perform better than LVEF alone in identifying high risk patients. 
The number of deaths recognized by both methods are nearly identical. However the sample of 
high risk patients is much smaller using the new criteria with a reduction of 19.7 % and a range 
between 4 % and 29 %. 
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Figure 2:  The result within 100 bootstrap samples comparing the size of the high risk group 
and the corresponding positive predictive value (ppv) for the two decision rules 
considered (LVEF ≤ 30 % and the new one). The result obtained in the original 
data are marked (x). 
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Cost effectiveness 
A major concern for identifying patients suitable for implanting an ICD are the costs26, 27. 
The estimation of the total costs is based on the following assumption that the implantation of an 
ICD is about € 30,000.- and € 150.- are required for performing a Holter-ECG. 
Using only LVEF for the decision no Holter-ECG has to be performed. In applying LVEF in 
combination with TS an additional Holter-EGG is necessary if LVEF is between 21 % and 40 %. 
If LVEF is above 40 % the patients belongs to the low-risk group and with a LVEF ≤ 20 % this is 
a high risk patient independent of the TS-status. 
Considering both studies 705 out of the 1172 patients had a LVEF between 21 % and 40 %. 
The average costs for both criterias are as follows. 
a) LVEF ≤ 30 %: 375 ICD * € 30,000.- = Mio. € 11.25 
b) new criteria: 301 ICD * € 30,000.- + 705 Holter * € 150.- = Mio. €   9.14 
Applying the new criteria the high risk group can be reduced and therefore also in the costs of 
about 19 %. 
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Discussion 
In the original study13, LVEF was dichotomized at ≤ 30 % vs. > 30 %, and it was determined that 
LVEF and TS were the only significant and independent predictors of mortality. In the current 
analyses, we evaluated the association between LVEF and mortality and chose to use LVEF, 
logarithically transformed, as a continuous variable in all analyses.  
We proceeded to develop a risk stratification algorithm which utilized both risk predictors, LVEF 
alone and in combination with TS. The model makes use of different LVEF cut-off points in the 
patient subgroups with normal and abnormal TS achieving desired levels of sensitivity and 
positive predictive accuracy.  
The optimal separation of low- and high-risk groups remains a different task. With decreasing 
number of patients in the high risk group the mortality rate increases. The cost-effectiveness 
therefore is also increasing. However one has to take into account that the so-called low-risk 
groups contains more and more deaths. But in any case the definition of the criteria for being a 
high-risk patients remains a problem. One can use the 2 year mortality rate as criterion. In this 
situation one gets different cutpoints for LVEF depending on turbulence slope. In order to 
compare the effect of the new procedure with the established one (LVEF ≤ 30 %), the following 
cutpoints have been derived using the data of both studies together (MPIP and EMIAT). 
TS normal: LVEF ≤ 20 % 
TS abnormal: LVEF ≤ 40 % 
Using these criteria a Holter-ECG has to be performed for patients with a LVEF between 21 and 
40 %. Based on these definitions of high-risk 301 patients are fulfilling these criteria with 
83 deaths. On the other hand 375 patients have a LVEF ≤ 30 % with 85 deaths. This means 
applying the new criteria the high-risk group can be reduced by about 19 % with nearly equal 
number of deaths or similar sensitivity. 
Several authors have addressed the problems associated with risk stratification. In post-MI 
patients there may be a variety of causes of death. All the markers available my be correlated with 
cardiac death, which accounts for about 60 % of all deaths. The markers may be inadequate for 
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other causes. But it seems that the process of identifying high risk patients is still an important 
task and the problem can be solved step by step. In this way the combination of LVEF and 
turbulence slope is one step to reduce the number of high risk patients. The next step will be 
investigate whether the patients identified as having a high risk truely benefit from an ICD. There 
is still room for developing new and more specific markers.  
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